Tag: Addiction
FDA Allows Marketing of Vuse Tobacco-Flavored Vapes
By Robin Foster HealthDay Reporter
FRIDAY, July 19, 2024 (HealthDay News) -- The U.S. Food and Drug Administration on Thursday authorized the sale of the...
FDA’s Move to OK First Menthol Vapes Is Big Mistake, Health Advocates Say
By Robin Foster HealthDay Reporter
MONDAY, June 24, 2024 (HealthDay News) -- The U.S. Food and Drug Administration's decision to authorize the first menthol-flavored e-cigarettes...
FDA, DOJ Form Task Force to Fight Illegal Vapes
By Robin Foster HealthDay Reporter
TUESDAY, June 11, 2024 (HealthDay News) -- The U.S. Food and Drug Administration announced Monday that it has joined up...
College Student Use of 988 Suicide and Crisis Lifeline for Substance Use Limited
Students less likely to use 988 Lifeline for substance use concerns compared with other mental health concerns
Reduced Stimulant Use Linked to Improvement in Indicators of Recovery
Reduced use associated with decreases in craving for primary drug, drug-seeking behaviors, depression severity
FDA Approves DNA Cheek Swab Test to ID Patients at High Risk for Opioid...
In clinical trials, the test accurately assessed a raised risk for addiction 83 percent of the time
Psychostimulants Beneficial for Amphetamine-Type Stimulant Use Disorder
Higher doses of prescription psychostimulants, treatment duration positively linked to longer retention
One-Day Induction of XR Buprenorphine Feasible for Fentanyl Use in OUD
Rapid induction to extended-release buprenorphine 300-mg injection feasible and well tolerated for those using fentanyl
Telemedicine Feasible for Buprenorphine Initiation in Opioid Use Disorder
Higher 90-day treatment retention rates seen with no higher risk for overdose
No Meaningful Increase Seen in New Opioid Use Disorder Diagnoses With Routine Screening
Implementation of opioid use disorder screening does not increase percentage of patients with new diagnosis
